Laurus Labs Limited (NSE:LAURUSLABS)
India · Delayed Price · Currency is INR | Market Cap | 518.04B |
| Revenue (ttm) | 63.58B |
| Net Income (ttm) | 6.84B |
| Shares Out | 539.82M |
| EPS (ttm) | 12.67 |
| PE Ratio | 75.77 |
| Forward PE | 64.23 |
| Dividend | 1.60 (0.17%) |
| Ex-Dividend Date | Oct 31, 2025 |
| Volume | 2,714,923 |
| Average Volume | 2,624,932 |
| Open | 941.00 |
| Previous Close | 940.15 |
| Day's Range | 936.80 - 962.70 |
| 52-Week Range | 459.55 - 962.70 |
| Beta | 0.34 |
| RSI | 71.71 |
| Earnings Date | Oct 28, 2025 |
About Laurus Labs
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition,... [Read more]
Financial Performance
In 2024, Laurus Labs's revenue was 55.54 billion, an increase of 10.18% compared to the previous year's 50.41 billion. Earnings were 3.58 billion, an increase of 123.18%.
Financial StatementsNews
DAM Capital bullish on Laurus Labs, cites CDMO traction and lower net debt in strong Q2
DAM Capital has reiterated its buy rating on Laurus Labs with a target price of ₹1,083 per share after a...
Goldman Sachs cautious on Laurus despite 126% YoY EBITDA growth; valuations seen full
Goldman Sachs has maintained its sell rating on Laurus Labs with a target price of ₹775 per share following a...
Jefferies cautious on Laurus Labs despite Q2 beat; $600m Vizag capex to extend investment cycle
Jefferies has maintained its underperform rating on Laurus Labs while raising its target price to ₹700 per share following the...
Laurus Labs reports sharp rise in profit and revenue for second quarter of 2025
Hyderabad: Laurus Labs on Thursday said it saw an 875% jump in consolidated net profit for the second quarter ended Sept 30, 2025, at ₹195 crore from .
Laurus Labs Ltd (BOM:540222) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and ...
Laurus Labs Ltd (BOM:540222) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic Investments
Q2 2026 Laurus Labs Ltd Earnings Call Transcript
Q2 2026 Laurus Labs Ltd Earnings Call Transcript
Laurus Labs in focus as brokerage firm B&K gives Buy call just ahead of Q2 results today
B&K Securities has initiated coverage on Laurus Labs with a buy rating and a target price of ₹1,030 per share,...
Top stocks to buy in Diwali week: Stock recommendations for the week starting October 20, 2025 - check list
Motilal Oswal Financial Services has identified Hyundai Motor and Laurus Labs as top stock picks for Diwali week. Hyundai plans a massive investment in R&D and capacity expansion, aiming for significa...
Divi’s Lab and Laurus Labs in focus as August export data signals strong growth
Pharma majors Divi’s Laboratories and Laurus Labs are in spotlight after fresh August 2025 export data highlighted robust momentum in shipments. Laurus Labs reported export value of USD 37.4 million i...
Laurus Labs to dissolve CDMO arm Laurus Synthetics as part of rejig
Hyderabad: In a restructuring exercise, Laurus Labs is demerging Unit-1, which is the API manufacturing component of its contract development and manu.
Why are Laurus Labs shares up over 2% today? Explained
Shares of Laurus Labs Ltd surged over 2% to ₹856.25 in early trade on Monday, making it one of the top gainers on the NSE. The sharp upmove comes on the back of a stellar Q1 performance, a major land ...
Stocks to watch on brokerages, July 28: Mphasis, Cipla, Kotak Bank, Laurus Labs, IDFC First Bank, Bank of Baorda, SBI Cards, and more in focus
A full of brokerage actions is likely to impact several stocks on July 28, as global and domestic firms issued fresh views following earnings and business developments. Key names on the radar include ...
Antique maintains hold on Laurus Labs, raises target to Rs 700 as CDMO momentum persists but visibility stays limited
Antique Stock Broking has maintained a Hold rating on Laurus Labs, while raising its target price to ₹700 from ₹520, reflecting a more balanced view on the company’s growth outlook despite ongoing exe...
Motilal Oswal maintains buy on Laurus Labs, raises target to Rs 970 on strong CDMO-led earnings momentum
Motilal Oswal Financial Services (MOSL) has maintained a Buy rating on Laurus Labs, raising its target price to ₹970 from ₹860. The revised target suggests continued confidence in the company’s growth...
Kotak Institutional Equities maintains sell on Laurus Labs, raises target to Rs 555 as earnings recovery seen priced in
Kotak Institutional Equities has reiterated a Sell rating on Laurus Labs, while raising the target price to ₹555, implying a sharp downside of approximately 34% from the current market price of ₹839.9...
Jefferies maintains underperform on Laurus Labs, raises target to Rs 590 as margin concerns persist despite Q1 beat
Jefferies has maintained an Underperform rating on Laurus Labs, while raising its target price to ₹590 — implying a downside of approximately 29.8% from the current market price of ₹839.90. The compan...
Goldman Sachs maintains sell on Laurus Labs, raises target to Rs 675 citing limited visibility despite margin optimism
Goldman Sachs has maintained a Sell rating on Laurus Labs, while raising the target price to ₹675. The revised target implies a downside of approximately 20% from the current market price of ₹839.90. ...
Laurus Labs posts sharp rise in net profit for Q1FY26
Hyderabad: Pharma player Laurus Labs has posted a significant 1,154% rise in net profit for the quarter ended June 30, 2025, at Rs 163 crore compared .
Stocks to watch on Q1 results today, July 25: Bajaj Finserv, Bank of Baroda, Cipla, SAIL, SBICard, Shriram Finance, and 40 others in focus
Indian equities are set for an action-packed session on Thursday, July 25, as several major and mid-sized companies will announce their financial results for the first quarter of FY26. Among the key n...
Top stocks at 52-week highs today, July 15: RBL Bank, Force Motors, Laurus Labs, CSB Bank and more
Indian markets began the week with strong gains on Monday, July 15, as the BSE Sensex rallied 317 points to close at 82,570.91, while the NSE Nifty 50 advanced 113.5 points to end at 25,195.80. The bu...
Stocks hitting 52-week highs today, June 16: Bharat Electronics, Laurus Labs, Max Healthcare, JK Cement and more
Indian equity markets closed on a positive note on June 16, 2025, as benchmark indices posted strong gains across the board. The BSE Sensex surged 677.55 points (0.84%) to close at 81,796.15, while th...
Laurus Labs shares in focus as pharma exports for May 2025 double YoY
Shares of Laurus Labs were trading up by 0.91% at ₹672.65 on June 16 after India’s pharma export data for May 2025 revealed a strong performance by the company. According to official trade data, Lauru...
Laurus Labs Q4 Results: Revenue up 19.4% to Rs 1,720 crore, Net profit surges 210% YoY
Laurus Labs Ltd. reported strong financial performance for the quarter ended March 31, 2025 (Q4FY25), with a remarkable 211% year-on-year (YoY) increase in net profit, driven by higher revenues and a ...
Stocks hitting 52-week highs today, April 23: Laurus Labs, UPL, Bharti Hexacom, HDFC Bank and more
The Indian equity markets ended Wednesday, April 23, 2025, on a bullish note with major benchmark indices witnessing a sharp rally. The Nifty 50 surged past the 24,300 mark, closing at 24,328.95, up 1...
Stocks hitting 52-week highs today, April 22: HDFC Bank, Laurus Labs, Bharti Hexacom, Eicher Motors and more
The Indian stock market continued its upward trajectory for the sixth consecutive trading session on April 22, 2025. Both benchmark indices ended in green, with the BSE Sensex rising by 187.09 points ...